Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role

  Merck Announces Appointment of Robert M. Davis as Chief Financial Officer;
  Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007

Business Wire

WHITEHOUSE STATION, N.J. -- March 27, 2014

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today
announced the appointment of Robert M. Davis, 47, as executive vice president
and chief financial officer, effective April 23, 2014. Davis, who will also
oversee corporate strategy and corporate business development, will succeed
Peter N. Kellogg, 58. After having made significant contributions to the
company as Merck’s CFO since 2007, Kellogg will work closely with Davis to
ensure a seamless transition and will leave Merck on May 16.

"Rob is an accomplished executive with significant financial and operational
expertise, including as a CFO, and will be an exceptional addition to our
team,” said Kenneth C. Frazier, chairman and chief executive officer, Merck.
“Rob’s broad, global business and healthcare experience, which encompasses
commercial, R&D, quality, regulatory, manufacturing and supply chain, will be
an asset to us in implementing a significantly streamlined, more flexible cost
structure and operating model, while enabling us to focus on our
highest-potential growth opportunities.”

Davis is corporate vice president and president of Baxter’s Medical Products
business where he oversaw the successful integration of that company’s Global
Medication Delivery and Renal businesses, along with corporate manufacturing
and R&D functions, into a single, integrated division, improving R&D
productivity and eliminating significant costs. Prior to his current role,
Davis served as corporate vice president and president of Baxter’s Renal
business, as corporate vice president and chief financial officer from May of
2006 through May of 2010, and as treasurer from 2004 through May of 2006.
Davis joined Baxter as treasurer in 2004 after more than 14 years at Eli Lilly
and Company.

"It is a tremendous opportunity to join Merck at such an exciting time,” said
Davis. “Merck’s long-standing commitment to science, innovation and improving
global health is unsurpassed among pharmaceutical companies.”

Kellogg joined Merck in 2007 as executive vice president and chief financial
officer. He played a major role in driving the execution of Merck’s merger
with Schering-Plough and in designing the company’s capital structure to
enhance shareholder returns, including its 2013 accelerated share repurchase
program. To ensure a smooth transition, Kellogg will oversee the closing and
reporting of the company’s first quarter sales and earnings on April 29.

"Peter has been an important member of the Merck leadership team and
instrumental in helping to guide Merck during a period of significant change
at our company and in our industry,” said Frazier. “Peter leaves Merck a
stronger company, better positioned to deliver long-term value to our

"I am extremely proud of what we have accomplished together during my seven
year tenure at Merck,” said Kellogg. “And while I am excited to open another
chapter of my professional life, it is heartening that I can do so having had
the opportunity to contribute to Merck’s legacy and long-term success.”

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside of the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit and
connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck patents
and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2013
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site


Steven Cragle, 908-423-3461
Pam Eisele, 267-305-3558
Carol Ferguson, 908-423-4465
Justin Holko, 908-423-5088
Press spacebar to pause and continue. Press esc to stop.